mRNA Expression, measured by quantitative reverse transcriptase polymerase chain reaction, of five putative drug resistance parameters, in normal and leukaemic peripheral blood and bone marrow

Acta Haematologica

Volumn 98, Issue 1, 1997, Pages 1-7

  Lohri, Andreas ^a,b   van Hille, Benoît ^a   Reuter, Jürgen ^a   Tichelli, Andre ^c   Herrmann, Richard ^a,b  

^a Department of Research   (Germany)

^b Division of Oncology   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Acute myeloid leukaemia; Drug resistance; Quantitative reverse transcription polymerase chain reaction; Topoisomerase II and alpha

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE TRANSFERASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PROTEIN; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER RESISTANCE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; BONE MARROW; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENES, MDR; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA-DIRECTED DNA POLYMERASE;

EID: 0030925196     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203545     Document Type: Article

References (28)

1. Gsur A, Zochbauer S, Gotzl M, Kyrle PA, Lechner K, Pirker R: MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: An update. Leuk Lymphoma 1993; 12:91-94.
2. Tidcfelt U, Elmhom-Roscnborg A, Paul C, Hao X, Mannervik B. Erkisson LC: Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukaemia. Cancer Res 1992; 52:3281-3285.
3. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-3096.
4. Cole SP, Bhardwaj G, Gerlach JH, Mackic JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258: 1650-1654.
5. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P: Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993;53: 1475-1479.
6. Van Hille B, Lohri A, Reuter J, Herrmann R: Nonradioactive quantification of mdrl-mRNA by polymerase chain reaction amplification coupled with HPLC. Clin Chcm 1995; 41:1087-1093.
7. Barrand MA, Heppell Parton AC, Wright KA, Rabbitts PH, Twentyman PR: A 190-kilodal-ton protein overexpressed in non-P-glycopro-tein-containing multidrug-rcsistant cells and its relationship to the MRP gene. J Natl Cancer Inst 1994;86:110-117.
8. Grant CE, Valdimarsson G, Hipfncr DR, Almquist KC, Cole SP, Deeley RG: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357-361.
9. Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54:4313.
10. Vaux DL: Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 1993;90:786-789.
11. Miyashita T, Reed JC: bcl-2 gene transfer increases relative resistance of S491 and WEH171 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992;52:5407-5411.
12. Pommier Y, Leteurtre F, Fesen MR, Fujimori A. Bertrand R, Solary E, Kohlhagcn G, Kolin KW: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994:12:530-542.
13. Evans CD, Mirski SE, Danks MK. Cole SP: Reduced levels of topoisomerase II alpha and II beta in a multidrug-reistant lung-canccr cell line. Cancer Chemother Pharmacol 1994;34: 242-248.
14. Dalton WS., Dune BGM., Alberts DS., Gerlach JH, Cress AE: Characterization of a new drug-resistant human myeloma cell line that expresses p-glycoprotein. Cancer Res 1986;46: 5125-5130.
15. Bellamy WT, Dalton WS. Meltzcr P, Dorr RT: Role of glutathione and its associated enzymes in n ultidrug-rcsistant human myeloma cells. Biochem Pharmacol 1989;38:787-793.
16. Cole SPC, Chanda ER, Dicke FP., Gerlach JH, Mirski SEL: Non-p-glycoprotcin mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991 ;51: 3345-3352.
17. Nakajima Iijima S, Hamada H., Reddy P., Ka-kunaga T: Molecular structure of the human cytoplasmic beta-actin gene: Interspecics homology of sequences in the introns. Proc Natl Acad Sci USA 1985;82:6133-6137.
18. Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdrl (p-glycoprotcin) gene from multidrug-resistant human cells. Cell 1986;47:381-389.
19. Kano T, Sakai M, Muramatsu M: Structure and expression of a human class pi glutathione S-transfcrase messenger RNA. Cancer Res 1987;47:5626-5630.
20. Chung TDY, Drake FH, Tan KB, Per SR, Crooke ST. Mirabelli CK: Characterization and immunological identification of cDNA clones encoding two human DNA topoisomer-ase II isozymes. Proc Natl Acad Sci USA 1989; 86:9431-9435.
21. Clearly ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14; 18) translocation. Cell 1986; 47:19-28.
22. Drach D. Zhao S, Drach J, Mahadevia R, Gat-tringer C, Huber H, Andreeff M: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:2729-2734.
23. Gekeler V, Frese G, Noller A, Handgretinger R, Wilisch A, Schmidt H, Muller CP, Dopfer R, Klingebiel T, Diddens H: Mdrl/P-glycopro-tein, topoisomerase, and glutathione-S-trans-ferase pi gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer 1992;66:507-517.
24. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS: Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 1994;54:4676-4679.
25. Schneider E, Cowan KH. Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995;85:186-193.
26. Aiello A, Delia D, Borello MG, Biassoni D, Giardini R, Fontanella E, Pczzclla F, Pulford K, Pierotti M, Della Porta G: Flow cytometric detection of the mitochondrial bcl-2 protein in normal and neoplastic human lymphoid cells. Cytometry 1992;13:502-509.
27. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA, Della Porta G: bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992;79:1291-1298.
28. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ: Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994;83:517-530.